This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Iloprost" – news · newspapers · books · scholar · JSTOR (December 2010) (Learn how and when to remove this template message) This article contains close paraphrasing of non-free copyrighted sources. Relevant discussion may be found on the talk page. Please help rewriting it with your own words. (February 2024) (Learn how and when to remove this template message) This article may be in need of reorganization to comply with Wikipedia's layout guidelines. Please help by editing the article to make improvements to the overall structure. (February 2024) (Learn how and when to remove this template message) This article may need to be rewritten to comply with Wikipedia's quality standards. You can help. The talk page may contain suggestions. (February 2024) (Learn how and when to remove this template message)

Iloprost
Clinical data
Trade namesVentavis, Ilomedine, Aurlumyn
AHFS/Drugs.comMonograph
MedlinePlusa612032
License data
Routes of
administration		Inhalation, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNot determined[1]
Protein binding60%[1]
MetabolismVia β-oxidation to inactive tetranor-iloprost[1]
Elimination half-life20–30 minutes[1]
ExcretionRenal (68%) and fecal (12%)[1]
Identifiers
  • 5-{(E)-(1S,5S,6R,7R)-7-hydroxy-6[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-bicyclo[3.3.0]octan-3-ylidene}pentanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.163.887 Edit this at Wikidata
Chemical and physical data
FormulaC22H32O4
Molar mass360.494 g·mol−1
3D model (JSmol)
  • CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
  • InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 ☒N
  • Key:HIFJCPQKFCZDDL-ACWOEMLNSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues.[4] Iloprost is a prostacyclin mimetic.[1]

For pulmonary arterial hypertension, iloprost is given via inhalation. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through them. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in the European Union and by Actelion Pharmaceuticals in the US.

Medical uses

In the US, iloprost is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration.[1]

In the EU, iloprost is indicated for the treatment of people with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.[3]

In February 2024, the US Food and Drug Administration approved iloprost (Aurlumyn) to treat severe frostbite to reduce the risk of finger or toe amputation.[2][5]

Clinical pharmacology

Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer. While Iloprost is an analog of PGI2 that activates PGI2's receptor, the prostacyclin receptor, to stimulate vasodilation, it has little selectivity in that it binds to and activates all four receptors for prostaglandin E2 viz., prostaglandin EP1 receptor, prostaglandin EP2 receptor, prostaglandin EP3 receptor, and prostaglandin EP4 receptor.[6] Activation of the EP2 and EP4 receptors cause vasodilation but activation of the EP3 receptor causes vasoconstriction.

Contraindications

Contraindications include: unstable angina; within 6 months of myocardial infarction; decompensated cardiac failure (unless under close medical supervision); severe arrhythmias; congenital or acquired heart-valve defects; within 3 months of cerebrovascular events; pulmonary veno-occlusive disease; conditions which increase risk of bleeding.

Common side effects

In clinical studies, common adverse reactions due to inhaled iloprost included: vasodilation (flushing, 27%), cough (39%), headache (30%), flu syndrome (14%), nausea (13%), neck spasms (12%), hypotension (11%), insomnia (8%), and fainting (syncope) (8%); other serious adverse events reported with the use of Ventavis included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, swelling of the limbs (especially around the ankles and feet), and kidney failure.

Serious adverse events reported with the use of inhaled iloprost include congestive heart failure, chest pain, supraventricular tachycardia, shortness of breath, peripheral edema, and kidney failure.

References

  1. ^ a b c d e f g h "Ventavis- iloprost solution". DailyMed. 26 July 2022. Archived from the original on 19 February 2024. Retrieved 19 February 2024.
  2. ^ a b "Aurlumyn (iloprost) injection, for intravenous use" (PDF). Archived (PDF) from the original on 19 February 2024. Retrieved 19 February 2024.
  3. ^ a b "Ventavis EPAR". European Medicines Agency (EMA). 26 August 2013. Archived from the original on 12 November 2020. Retrieved 19 February 2024.
  4. ^ "Iloprost Information" (PDF). Archived from the original (PDF) on 6 April 2016. Retrieved 5 February 2009.
  5. ^ "FDA Approves First Medication to Treat Severe Frostbite" (Press release). U.S. Food and Drug Administration (FDA). 14 February 2024. Archived from the original on 16 February 2024. Retrieved 16 February 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ Moreno JJ (February 2017). "Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis". European Journal of Pharmacology. 796: 7–19. doi:10.1016/j.ejphar.2016.12.004. PMID 27940058. S2CID 1513449.

Further reading

Categories